TSVT News and Press, 2seventy bio Inc. From 03/15/24

The supplemental Biologics License Application for Abecma in this indication remains under review with the FDA; Abecma has been approved in Japan and Switzerland and received a positive CHMP Opinion by the European Medicines Agency based on KarMMa-3 Bristol Myers Squibb (N...

2024-03-15 13:25:53 ET More on J&J, Legend Biotech, etc. Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade) Johnson & Johnson (JNJ) Barclays 26th Annual Global Healthcare Conference (Transcript) Johnson & Johnson (JNJ) Leerink P...

2024-03-13 09:23:45 ET More on Bristol-Myers, Johnson & Johnson, etc. Johnson & Johnson (JNJ) Leerink Partners Global Biopharma Conference (Transcript) Bristol-Myers Squibb: Finally Trending Up Bristol-Myers Squibb: Turnaround Expected J&J submits...

2024-03-08 04:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...

2024-03-05 12:57:03 ET 2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Conference Call March 05, 2024, 08:00 ET Company Participants Elizabeth Hickin - Head, IR Chip Baird - Incoming CEO Vicki Eatwell - Incoming CFO Anna Truppel-Hartmann - SVP, Clinical Developmen...

2024-03-05 07:04:54 ET More on 2seventy bio 2seventy bio: An Overload Of Troubles At This Small Pharma Bristol Myers, 2seventy bio to face FDA panel in March for Abecma decision Leerink ups 2seventy to outperform, cites attractiveness as takeover target Seeki...

New strategic path forward as Abecma- focused company announced in January 2024; on track to close Asset Sale of R&D pipeline to Regeneron in the first half of 2024 U.S. Food and Drug Administration Oncologic Drugs Advisory Committee scheduled for March 15, 2024, to review data su...

Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...

2seventy bio, Inc . (Nasdaq: TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Members of the management team will also be presenting at the following upcoming investor conferenc...